Nonsmall cell lung cancer therapy: Insight into multitargeted small-molecule growth factor receptor inhibitors

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Roy, Mridul ^a   Luo, Yu Hao ^a   Ye, Mao ^b   Liu, Jing ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; BRIVANIB; CEDIRANIB; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; ERLOTINIB; FIGITUMUMAB; GANITUMAB; GEMCITABINE; GROWTH FACTOR RECEPTOR; IMC 11F 8; IMC 3G 3; IXABEPILONE; LINIFANIB; MATUZUMAB; MOTESANIB; NECITUMUMAB; NIMOTUZUMAB; NINTEDANIB; OLARATUMAB; PANITUMUMAB; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; XL 647; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; MOLECULAR LIBRARY;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CARCINOGENIC ACTIVITY; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NAUSEA; PROTEINURIA; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; VOMITING; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; GENETICS; LUNG TUMOR; MOLECULAR LIBRARY; PATHOLOGY; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; SMALL MOLECULE LIBRARIES;

EID: 84880855549     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/964743     Document Type: Review

References (98)

1. American Cancer Society, Cancer facts and figures 2013. American Cancer Society, Atlanta, Ga, USA, 2013, http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-036845.pdf
2. American Cancer Society, Non-small cell lung cancer. 2013, http://www.cancer.org/cancer/lungcancer-non-smallcell/index
3. Ettinger D. S., Akerley W., Borghaei H., Non-small cell lung cancer. Journal of the National Comprehensive Cancer Network 2012 10 10 1236 1271
4. Fossella F., Pereira J. R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., Mattson K. V., Ramlau R., Szczsna A., Fidias P., Millward M., Belani C. P., Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group. Journal of Clinical Oncology 2003 21 16 3016 3024 2-s2.0-0042413836 10.1200/JCO.2003.12.046 (Pubitemid 46606280)
5. Scagliotti G. V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., Serwatowski P., Gatzemeier U., Digumarti R., Zukin M., Lee J. S., Mellemgaard A., Park K., Patil S., Rolski J., Goksel T., De Marinis F., Simms L., Sugarman K. P., Gandara D., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology 2008 26 21 3543 3551 2-s2.0-49049089802 10.1200/JCO.2007.15.0375
6. Carney D. N., Lung cancer-time to move on from chemotherapy. New England Journal of Medicine 2002 346 2 126 128 2-s2.0-0037050355 10.1056/ NEJM200201103460211 (Pubitemid 34438905)
7. von Plessen C., Bergman B., Andresen O., Bremnes R. M., Sundstrøm S., Gilleryd M., Stephens R., Vilsvik J., Aasebø U., Sörenson S., Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. British Journal of Cancer 2006 95 8 966 973 2-s2.0-33750207905 10.1038/sj.bjc.6603383 (Pubitemid 44606820)
8. Joon O. P., Kim S. W., Jin S. A., Suh C., Jung S. L., Joung S. J., Eun K. C., Sung H. Y., Choi J. H., Dae S. H., Suk Y. P., Sang W. S., Myung J. A., Jong S. L., Young H. Y., Lee J. W., Park K., Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer. Journal of Clinical Oncology 2007 25 33 5233 5239 2-s2.0-36849019938 10.1200/JCO.2007.10.8134 (Pubitemid 350232255)
9. Jemal A., Center M. M., DeSantis C., Ward E. M., Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology Biomarkers and Prevention 2010 19 8 1893 1907 2-s2.0-77955462853 10.1158/1055-9965.EPI-10- 0437
10. Hanahan D., Weinberg R. A., The hallmarks of cancer. Cell 2000 100 1 57 70 2-s2.0-0034614637 10.1016/S0092-8674(00)81683-9 (Pubitemid 30046295)
11. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J. Y., Nishiwaki Y., Vansteenkiste J., Kudoh S., Rischin D., Eek R., Horai T., Noda K., Takata I., Smit E., Averbuch S., Macleod A., Feyereislova A., Dong R. P., Baselga J., Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. Journal of Clinical Oncology 2003 21 12 2237 2246 (Pubitemid 46621858)
12. Toschi L., Cappuzzo F., Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 2007 12 2 211 220 2-s2.0-33847068819 10.1634/theoncologist.12-2-211
13. Pennell N. A., Lynch T. J. Jr., Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 2009 14 4 399 411 2-s2.0-66249135629 10.1634/theoncologist.2008-0276
14. Fontanini G., Vignati S., Boldrini L., Chiné S., Silvestri V., Lucchi M., Mussi A., Angeletti C. A., Bevilacqua G., Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clinical Cancer Research 1997 3 6 861 865 2-s2.0-0030969559 (Pubitemid 27252933)
15. Wang Y., Huang L., Yang Y., Xu L., Yang J., Wu Y., Effects of autocrine vascular endothelial growth factor (VEGF) in non-small cell lung cancer cell line A549. Molecular Biology Reports 2013 40 4 3093 3099
16. Charpidou A., Gkiozos I., Konstantinou M., Eleftheraki A., Demertzis P., Harrington K., Polyzos A., Syrigos K. N., Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients. Cancer Letters 2011 304 2 144 153 2-s2.0-79952736586 10.1016/j.canlet.2011.02.018
17. Ferrara N., Gerber H. P., LeCouter J., The biology of VEGF and its receptors. Nature Medicine 2003 9 6 669 676 2-s2.0-0037699954 10.1038/nm0603-669 (Pubitemid 36749215)
18. Levitzki A., PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine and Growth Factor Reviews 2004 15 4 229 235 2-s2.0-2942630916 10.1016/j.cytogfr.2004.03.010 (Pubitemid 38781048)
19. Reinmuth N., Liersch R., Raedel M., Fehrmann F., Fehrmann N., Bayer M., Schwoeppe C., Kessler T., Berdel W., Thomas M., Mesters R. M., Combined anti-PDGFRalpha and PDGFRbeta targeting in non-small cell lung cancer. International Journal of Cancer 2009 124 7 1535 1544 2-s2.0-61449103756 10.1002/ijc.24109
20. Donnem T., Al-Saad S., Al-Shibli K., Busund L. T., Bremnes R. M., Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Annals of Oncology 2010 21 2 223 231 2-s2.0-77950402591 10.1093/annonc/mdp296
21. Beenken A., Mohammadi M., The FGF family: biology, pathophysiology and therapy. Nature Reviews Drug Discovery 2009 8 3 235 253 2-s2.0-61649100307 10.1038/nrd2792
22. Knowlden J. M., Jones H. E., Barrow D., Gee J. M. W., Nicholson R. I., Hutcheson I. R., Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Research and Treatment 2008 111 1 79 91 2-s2.0-47549108868 10.1007/s10549-007-9763-9 (Pubitemid 352009232)
23. Semrad T. J., Mack P. C., Fibroblast growth factor signaling in nonsmall-cell lung cancer. Clinical Lung Cancer 2012 13 2 90 95 2-s2.0-84857407325 10.1016/j.cllc.2011.08.001
24. Nakagawa M., Uramoto H., Oka S., Chikaishi Y., Iwanami T., Shimokawa H., So T., Hanagiri T., Tanaka F., Clinical significance of IGF1R expression in nonsmall-cell lung cancer. Clinical Lung Cancer 2012 13 2 136 142 2-s2.0-84857383814 10.1016/j.cllc.2011.10.006
25. Desbois-Mouthon C., Baron A., Blivet-Van Eggelpoël M. J., Fartoux L., Venot C., Bladt F., Housset C., Rosmorduc O., Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clinical Cancer Research 2009 15 17 5445 5456 2-s2.0-69949106121 10.1158/1078-0432.CCR-08-2980
26. Ariga M., Nedachi T., Akahori M., Sakamoto H., Ito Y., Hakuno F., Takahashi S. I., Signalling pathways of insulin-like growth factor-I that are augmented by cAMP in FRTL-5 cells. Biochemical Journal 2000 348 2 409 416 2-s2.0-0034212443 10.1042/0264-6021:3480409 (Pubitemid 30345215)
27. Nguyen D. M., Schrump D. S., Growth factor receptors as targets for lung cancer therapy. Seminars in Thoracic and Cardiovascular Surgery 2004 16 1 3 12 2-s2.0-2642519008 (Pubitemid 38714754)
28. Imai K., Takaoka A., Comparing antibody and small-molecule therapies for cancer. Nature Reviews Cancer 2006 6 9 714 727 2-s2.0-33747855481 10.1038/nrc1913 (Pubitemid 44286003)
29. Reck M., Barlesi F., Crinò L., Henschke C. I., Isla D., Stiebeler S., Spigel D. R., Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Annals of Oncology 2012 23 5 1111 1120 2-s2.0-84860491472 10.1093/annonc/mdr463
30. Hudson P. J., Souriau C., Engineered antibodies. Nature Medicine 2003 9 1 129 134 2-s2.0-0037235949 10.1038/nm0103-129 (Pubitemid 36098274)
31. Gorter A., Meri S., Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunology Today 1999 20 12 576 582 2-s2.0-0033486076 10.1016/S0167-5699(99)01537-6
32. Zhang J., Yang P. L., Gray N. S., Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer 2009 9 1 28 39 2-s2.0-57749188299 10.1038/nrc2559
33. Johnson L. N., Protein kinase inhibitors: contributions from structure to clinical compounds. Quarterly Reviews of Biophysics 2009 42 1 1 40 2-s2.0-67649726156 10.1017/S0033583508004745
34. Liu Y., Gray N. S., Rational design of inhibitors that bind to inactive kinase conformations. Nature Chemical Biology 2006 2 7 358 364 2-s2.0-33745298429 10.1038/nchembio799 (Pubitemid 43936934)
35. Wan P. T. C., Garnett M. J., Roe S. M., Lee S., Niculescu-Duvaz D., Good V. M., Project C. G., Jones C. M., Marshall C. J., Springer C. J., Barford D., Marais R., Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004 116 6 855 867 2-s2.0-12144289677 10.1016/S0092-8674(04)00215-6 (Pubitemid 38410730)
36. Kwak E. L., Sordella R., Bell D. W., Godin-Heymann N., Okimoto R. A., Brannigan B. W., Harris P. L., Driscoll D. R., Fidias P., Lynch T. J., Rabindran S. K., McGinnis J. P., Wissner A., Sharma S. V., Isselbacher K. J., Settleman J., Haber D. A., Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proceedings of the National Academy of Sciences of the United States of America 2005 102 21 7665 7670 2-s2.0-21144439000 10.1073/pnas.0502860102 (Pubitemid 40741028)
37. Wissner A., Fraser H. L., Ingalls C. L., Dushin R. G., Floyd M. B., Cheung K., Nittoli T., Ravi M. R., Tan X., Loganzo F., Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. Bioorganic and Medicinal Chemistry 2007 15 11 3635 3648 2-s2.0-34247393271 10.1016/j.bmc.2007.03.055 (Pubitemid 46635150)
38. Dancey J. E., Agents targeting Ras signaling pathway. Current Pharmaceutical Design 2002 8 25 2259 2267 2-s2.0-0036399117 10.2174/ 1381612023393071 (Pubitemid 35189899)
39. Schiller J. H., Lee J., Hanna N., Traynor A., Carbone D D., A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens. Journal of Clinical Oncology 2008 26 supplement 15, article 427S
40. Scagliotti G., Novello S., von Pawel J., Reck M., Pereira J. R., Thomas M., Miziara J. E. A., Balint B., De Marinis F., Keller A., Arén O., Csollak M., Albert I., Barrios C. H., Grossi F., Krzakowski M., Cupit L., Cihon F., DiMatteo S., Hanna N., Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. Journal of Clinical Oncology 2010 28 11 1835 1842 2-s2.0-77951639655 10.1200/JCO.2009.26.1321
41. Wang Y., Wang L., Liu Y., Yu S., Zhang X., Shi Y., Sun Y., Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer. Chinese Journal of Lung Cancer 2011 14 3 239 244 2-s2.0-79953219112 10.3779/j.issn.1009-3419.2011.03.10
42. Paz-Ares L. G., Biesma B., Heigener D., Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. Journal of Clinical Oncology 2012 30 25 3084 3092
43. Lind J. S. W., Dingemans A. M. C., Groen H. J. M., Thunnissen F. B., Bekers O., Heideman D. A. M., Honeywell R. J., Giovannetti E., Peters G. J., Postmus P. E., Van Suylen R. J., Smit E. F., A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naïve patients with advanced non-small cell lung cancer. Clinical Cancer Research 2010 16 11 3078 3087 2-s2.0-77953114837 10.1158/1078-0432.CCR-09-3033
44. Gridelli C., Morgillo F., Favaretto A., de Marinis F., Chella A., Cerea G., Mattioli R., Tortora G., Rossi A., Fasano M., Pasello G., Ricciardi S., Maione P., di Maio M., Ciardiello F., Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Annals of Oncology 2011 22 7 1528 1534 2-s2.0-79959695837 10.1093/annonc/mdq630
45. Spigel D. R., Greco F. A., Shipley D. L., Friedman E. K., Waterhouse D. M., Whorf R. C., Mitchell R. B., Daniel D. B., Zangmeister J., Bass J. D., Hainsworth J. D., Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. Journal of Clinical Oncology 2011 29 18 2582 2589 2-s2.0-79959306917 10.1200/JCO.2010.30.7678
46. Adjei A., Blumenschein G. Jr., Mandrekar S., Hillman S., Gatzemeier U., Heigener D., Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. Clinical Lung Cancer 2011 12 4 212 217 2-s2.0-79960343099 10.1016/j.cllc.2011.03.021
47. Mendel D. B., Douglas Laird A., Xin X., Louie S. G., Christensen J. G., Li G., Schreck R. E., Abrams T. J., Ngai T. J., Lee L. B., Murray L. J., Carver J., Chan E., Moss K. G., Haznedar J. Ö., Sukbuntherng J., Blake R. A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J. M., In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research 2003 9 1 327 337 2-s2.0-12244301581 (Pubitemid 36109749)
48. Novello S., Scagliotti G. V., Rosell R., Socinski M. A., Brahmer J., Atkins J., Pallares C., Burgess R., Tye L., Selaru P., Wang E., Chao R., Govindan R., Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. British Journal of Cancer 2009 101 9 1543 1548 2-s2.0-70350655546 10.1038/sj.bjc.6605346
49. Novello S., Camps C., Grossi F., Mazieres J., Abrey L., Vernejoux J. M., Thall A., Patyna S., Usari T., Wang Z., Chao R. C., Scagliotti G., Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases. Journal of Thoracic Oncology 2011 6 7 1260 1266 2-s2.0-79959908104 10.1097/JTO.0b013e318219a973
50. Scagliotti G. V., Vynnychenko I., Park K., International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. Journal of Clinical Oncology 2012 30 23 2829 2836
51. Socinski M. A., Scappaticci F. A., Samant M., Kolb M. M., Kozloff M. F., Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. Journal of Thoracic Oncology 2010 5 3 354 360 2-s2.0-77649322923 10.1097/JTO.0b013e3181c7307e
52. Blumenschein G. R. Jr., Ciuleanu T., Robert F., Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study. Journal of Thoracic Oncology 2012 7 9 1406 1416
53. Nikolinakos P., Heymach J. V., The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. Journal of Thoracic Oncology 2008 3 6 S131 S134 2-s2.0-44649149619 10.1097/JTO. 0b013e318174e910 (Pubitemid 351786743)
54. Yamamoto N., Tamura T., Yamamoto N., Yamada K., Yamada Y., Nokihara H., Fujiwara Y., Takahashi T., Murakami H., Boku N., Yamazaki K., Puchalski T. A., Shin E., Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN ™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 2009 64 6, supplement 2 1165 1172 2-s2.0-69049085535 10.1007/s00280-009-0979-8
55. Goss G., Shepherd F. A., Laurie S., Gauthier I., Leighl N., Chen E., Feld R., Powers J., Seymour L., A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. European Journal of Cancer 2009 45 5 782 788 2-s2.0-61349124193 10.1016/j.ejca.2008.10.022
56. Goss G. D., Arnold A., Shepherd F. A., Dediu M., Ciuleanu T. E., Fenton D., Zukin M., Walde D., Laberge F., Vincent M. D., Ellis P. M., Laurie S. A., Ding K., Frymire E., Gauthier I., Leighl N. B., Ho C., Noble J., Lee C. W., Seymour L., Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. Journal of Clinical Oncology 2010 28 1 49 55 2-s2.0-73949092851 10.1200/JCO.2009.22.9427
57. Dy G. K., Mandrekar S. J., Nelson G. D., A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. Journal of Thoracic Oncology 2013 8 1 79 88
58. Albert D. H., Tapang P., Magoc T. J., Pease L. J., Reuter D. R., Wei R. Q., Li J., Guo J., Bousquet P. F., Ghoreishi-Haack N. S., Wang B., Bukofzer G. T., Wang Y. C., Stavropoulos J. A., Hartandi K., Niquette A. L., Soni N., Johnson E. F., McCall J. O., Bouska J. J., Luo Y., Donawho C. K., Dai Y., Marcotte P. A., Glaser K. B., Michaelides M. R., Davidsen S. K., Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics 2006 5 4 995 1006 2-s2.0-33646586669 10.1158/1535-7163.MCT-05-0410 (Pubitemid 43724600)
59. Asahina H., Tamura Y., Nokihara H., Yamamoto N., Seki Y., Shibata T., Goto Y., Tanioka M., Yamada Y., Coates A., Chiu Y. L., Li X., Pradhan R., Ansell P. J., McKeegan E. M., McKee M. D., Carlson D. M., Tamura T., An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemotherapy and Pharmacology 2012 69 6 1477 1486 2-s2.0-84857462803 10.1007/s00280-012-1846-6
60. Tan E. H., Goss G. D., Salgia R., Besse B., Gandara D. R., Hanna N. H., Yang J. C. H., Thertulien R., Wertheim M., Mazieres J., Hensing T., Lee C., Gupta N., Pradhan R., Qian J., Qin Q., Scappaticci F. A., Ricker J. L., Carlson D. M., Soo R. A., Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology 2011 6 8 1418 1425 2-s2.0-80051801904 10.1097/JTO.0b013e318220c93e
61. Choueiri T. K., Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Current Opinion in Investigational Drugs 2008 9 6 658 671 2-s2.0-44649151405 (Pubitemid 351777169)
62. Wang F., Mi Y. J., Chen S. G., Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. Molecular Medicine 2012 18 887 898
63. Kozloff M. F., Martin L. P., Krzakowski M., Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. British Journal of Cancer 2012 107 8 1277 1285
64. Raghav K. P. S., Blumenschein G. R., Motesanib and advanced NSCLC: experiences and expectations. Expert Opinion on Investigational Drugs 2011 20 6 859 869 2-s2.0-79955827262 10.1517/13543784.2011.579103
65. Coxon A., Ziegler B., Kaufman S., Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Molecular Cancer 2012 11 70
66. Das M., Wakelee H., Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study. Journal of Thoracic Disease 2012 4 6 558 561
67. Wedge S. R., Ogilvie D. J., Dukes M., Kendrew J., Chester R., Jackson J. A., Boffey S. J., Valentine P. J., Curwen J. O., Musgrove H. L., Graham G. A., Hughes G. D., Thomas A. P., Stokes E. S. E., Curry B., Richmond G. H. P., Wadsworth P. F., Bigley A. L., Hennequin L. F., ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Research 2002 62 16 4645 4655 2-s2.0-0037102369
68. Zhang L., Li S., Zhang Y., Zhan J., Zou B. Y., Smith R., Martin P. D., Jiang Y., Liao H., Guan Z., Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clinical Therapeutics 2011 33 3 315 327 2-s2.0-79956029711 10.1016/j.clinthera.2011.04.005
69. Heymach J. V., Paz-Ares L., De Braud F., Sebastian M., Stewart D. J., Eberhardt W. E. E., Ranade A. A., Cohen G., Trigo J. M., Sandler A. B., Bonomi P. D., Herbst R. S., Krebs A. D., Vasselli J., Johnson B. E., Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. Journal of Clinical Oncology 2008 26 33 5407 5415 2-s2.0-56749102822 10.1200/JCO.2008.17.3138
70. De Boer R. H., Arrieta Ó., Yang C. H., Gottfried M., Chan V., Raats J., De Marinis F., Abratt R. P., Wolf J., Blackhall F. H., Langmuir P., Milenkova T., Read J., Vansteenkiste J. F., Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2011 29 8 1067 1074 2-s2.0-79952742483 10.1200/JCO.2010.29.5717
71. Herbst R. S., Sun Y., Eberhardt W. E. E., Germonpré P., Saijo N., Zhou C., Wang J., Li L., Kabbinavar F., Ichinose Y., Qin S., Zhang L., Biesma B., Heymach J. V., Langmuir P., Kennedy S. J., Tada H., Johnson B. E., Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. The Lancet Oncology 2010 11 7 619 626 2-s2.0-77954035012 10.1016/S1470-2045(10)70132-7
72. Lee J. S., Hirsh V., Park K., Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). Journal of Clinical Oncology 2012 30 10 1114 1121
73. Yu H. A., Riely G. J., Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. Journal of the National Comprehensive Cancer Network 2013 11 2 161 169
74. Pietanza M. C., Gadgeel S. M., Dowlati A., Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. Journal of Thoracic Oncology 2012 7 5 856 865
75. Gendreau S. B., Ventura R., Keast P., Laird A. D., Yakes F. M., Zhang W., Bentzien F., Cancilla B., Lutman J., Chu F., Jackman L., Shi Y., Yu P., Wang J., Aftab D. T., Jaeger C. T., Meyer S. M., De Costa A., Engell K., Chen J., Martini J. F., Joly A. H., Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clinical Cancer Research 2007 13 12 3713 3723 2-s2.0-34250791359 10.1158/1078-0432.CCR-06-2590 (Pubitemid 46955136)
76. Pietanza M. C., Lynch T. J. Jr., Lara P. N., Cho J., Yanagihara R. H., Vrindavanam N., Chowhan N. M., Gadgeel S. M., Pennell N. A., Funke R., Mitchell B., Wakelee H. A., Miller V. A., XL647-A multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. Journal of Thoracic Oncology 2012 7 1 219 226 2-s2.0-84655160812 10.1097/JTO.0b013e31822eebf9
77. Marathe P. H., Kamath A. V., Zhang Y., D'Arienzo C., Bhide R., Fargnoli J., Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemotherapy and Pharmacology 2009 65 1 55 66 2-s2.0-70349618646 10.1007/s00280-009-1002-0
78. Bhide R. S., Cai Z. W., Zhang Y. Z., Qian L., Wei D., Barbosa S., Lombarde L. J., Borzilleri R. M., Zheng X., Wu L. I., Barrish J. C., Kim S. H., Leavitt K., Mathur A., Leith L., Chao S., Wautlet B., Mortillo S., Jeyaseelan R. Sr., Kukral D., Hunt J. T., Kamath A., Fura A., Vyas V., Marathe P., D'Arienzo C., Derbin G., Fargnoli J., Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. Journal of Medicinal Chemistry 2006 49 7 2143 2146 2-s2.0-33645670595 10.1021/jm051106d
79. Bhide R. S., Lombardo L. J., Hunt J. T., Cai Z. W., Barrish J. C., Galbraith S., Jeyaseelan R. Sr., Mortillo S., Wautlet B. S., Krishnan B., Kukral D., Malone H., Lewin A. C., Henley B. J., Fargnoli J., The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Molecular Cancer Therapeutics 2010 9 2 369 378 2-s2.0-76649108900 10.1158/1535-7163.MCT-09-0472
80. Mekhail T., Masson E., Fischer B. S., Gong J., Iyer R., Gan J., Pursley J., Patricia D., Williams D., Ganapathi R., Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. Drug Metabolism and Disposition 2010 38 11 1962 1966 2-s2.0-78049386779 10.1124/dmd.110.033951
81. Jonker D. J., Rosen L. S., Sawyer M. B., de Braud F., Wilding G., Sweeney C. J., Jayson G. C., McArthur G. A., Rustin G., Goss G., Kantor J., Velasquez L., Syed S., Mokliatchouk O., Feltquate D. M., Kollia G., Nuyten D. S. A., Galbraith S., A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Annals of Oncology 2011 22 6 1413 1419 2-s2.0-79952967812 10.1093/annonc/mdq599
82. Lee F., Jure-Kunkel M. N., Salvati M. E., Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence. Therapeutic Advances in Medical Oncology 2011 3 1 11 25 2-s2.0-79952840120 10.1177/1758834010386402
83. Hilberg F., Roth G. J., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., Garin-Chesa P., Bader G., Zoephel A., Quant J., Heckel A., Rettig W. J., BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Research 2008 68 12 4774 4782 2-s2.0-49649123154 10.1158/0008-5472.CAN-07-6307
84. Reck M., Kaiser R., Eschbach C., Stefanic M., Love J., Gatzemeier U., Stopfer P., von Pawel J., A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Annals of Oncology 2011 22 6 1374 1381 2-s2.0-79957452054 10.1093/annonc/mdq618
85. Ellis P. M., Kaiser R., Zhao Y., Stopfer P., Gyorffy S., Hanna N., Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clinical Cancer Research 2010 16 10 2881 2889 2-s2.0-77952325749 10.1158/1078-0432.CCR-09-2944
86. Doebele R. C., Conkling P., Traynor A. M., A phase I, open-label dose-escalation study of continuous treatment with BIBF, 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Annals of Oncology 2012 23 8 2094 2102
87. Kumar R., Knick V. B., Rudolph S. K., Johnson J. H., Crosby R. M., Crouthamel M. C., Hopper T. M., Miller C. G., Harrington L. E., Onori J. A., Mullin R. J., Gilmer T. M., Truesdale A. T., Epperly A. H., Boloor A., Stafford J. A., Luttrell D. K., Cheung M., Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Molecular Cancer Therapeutics 2007 6 7 2012 2021 2-s2.0-34447322566 10.1158/1535-7163.MCT-07-0193 (Pubitemid 47052491)
88. Altorki N., Lane M. E., Bauer T., Lee P. C., Guarino M. J., Pass H., Felip E., Peylan-Ramu N., Gurpide A., Grannis F. W., Mitchell J. D., Tachdjian S., Swann R. S., Huff A., Roychowdhury D. F., Reeves A., Ottesen L. H., Yankelevitz D. F., Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. Journal of Clinical Oncology 2010 28 19 3131 3137 2-s2.0-77955503066 10.1200/JCO.2009.23.9749
89. Plummer R., Madi A., Jeffels M., A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 2013 71 1 93 101
90. Belani C. P., Goss G., Blumenschein G., Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treatment Reviews 2012 38 3 173 184 2-s2.0-84857658325 10.1016/j.ctrv.2011.05.009
91. Choi Y. L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakajima T., Yatabe Y., Takeuchi K., Hamada T., Haruta H., Ishikawa Y., Kimura H., Mitsudomi T., Tanio Y., Mano H., EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. New England Journal of Medicine 2010 363 18 1734 1739 2-s2.0-78049426513 10.1056/NEJMoa1007478
92. Langer C. J., Mok T., Postmus P. E., Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treatment Reviews 2013 39 3 252 260
93. Kim E. S., Herbst R. S., Wistuba I. I., The BATTLE trial: personalizing therapy for lung cancer. Cancer Discovery 1 1 44 53
94. Mok T. S., Wu Y. L., Thongprasert S., Yang C. H., Chu D. T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., Ohe Y., Yang J. J., Chewaskulyong B., Jiang H., Duffield E. L., Watkins C. L., Armour A. A., Fukuoka M., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine 2009 361 10 947 957 2-s2.0-69949162760 10.1056/NEJMoa0810699
95. Ladanyi M., Pao W., Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Modern Pathology 2008 21 supplement 2 S16 S22 2-s2.0-42549089715 10.1038/modpathol.3801018 (Pubitemid 351592769)
96. Miller V. A., Kris M. G., Shah N., Patel J., Azzoli C., Gomez J., Krug L. M., Pao W., Rizvi N., Pizzo B., Tyson L., Venkatraman E., Ben-Porat L., Memoli N., Zakowski M., Rusch V., Heelan R. T., Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. Journal of Clinical Oncology 2004 22 6 1103 1109 2-s2.0-1842509828 10.1200/JCO.2004.08.158 (Pubitemid 41095044)
97. Holgersson G., Bergström S., Bergqvist M., Nyman J., Hoye E., Helsing M., Friesland S., Holgersson M., Birath E., Ekman S., Blystad T., Ewers S. B., Mörth C., Löden B., Henriksson R., Swedish Lung Cancer Radiation Study Group: pedictive value of histology for radiotherapy response in patients with non-small cell lung cancer. European Journal of Cancer 2011 47 16 2415 2421 2-s2.0-80054909389 10.1016/j.ejca.2011.06.011
98. Engelman J. A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Joon O. P., Lindeman N., Gale C. M., Zhao X., Christensen J., Kosaka T., Holmes A. J., Rogers A. M., Cappuzzo F., Mok T., Lee C., Johnson B. E., Cantley L. C., Jänne P. A., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007 316 5827 1039 1043 2-s2.0-34249075147 10.1126/science.1141478 (Pubitemid 46799492)